Efruxifermin
drug drugOn this page
Also known as AKR-001AMG-876AMG876
Summary
Efruxifermin (CHEMBL4594389) is a phase-3 clinical-stage protein; indicated across 1 condition including metabolic dysfunction-associated steatotic liver disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594389 |
| Name | Efruxifermin |
| Type | Protein |
| Max phase | 3 |
Also known as: AKR-001, AMG-876, AMG876, Efruxifermin, EFRUXIFERMIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| metabolic dysfunction-associated steatotic liver disease | 1 | MONDO:0013209 | EFO:0003095 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06161571 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| NCT06215716 | PHASE3 | RECRUITING | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis |
| NCT06528314 | PHASE3 | RECRUITING | A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH |
| NCT04767529 | PHASE2 | COMPLETED | A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.